Developer docs
API playgroundTry for free, no card

Search company profiles

Mekonos

Full company profile

uuid0000sxa

Namestring
Mekonos
Websiteurl
mekonos.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Mekonos is a privately held biotech tools company founded in 2017 and headquartered in Alameda, California (Silicon Valley). It develops and commercializes Iris™, a proprietary system-on-a-chip platform that uses nano-needle technology to deliver payloads directly into cells, targeting pharmaceutical companies and research institutions working on cell therapies, gene therapies, and intracellular drug discovery. The platform is positioned as a more precise and less disruptive alternative to conventional intracellular delivery methods such as viral vectors, electroporation, and lipofection, with applications spanning ex vivo cell engineering and broader biotech research workflows.

The company's core technology centers on a semiconductor chip bearing arrays of nanoscale needles that physically interface with individual cells to deliver cargo, a method-architecture distinct from incumbent approaches. Its revenue model is described as one-time license/system sales of the Iris platform, and its go-to-market is enterprise field sales targeting biotech and pharmaceutical accounts. The company is venture-backed, having raised approximately $31 million cumulatively across seed, early, and Series A rounds between 2017 and 2021, with strategic investors including Novartis and Debiopharm Innovation Fund alongside deep-tech-focused capital such as TDK Ventures.

Mekonos operates with a team of 11–50 employees led by founder and CEO Anil Narasimha, with a leadership bench spanning operations (COO Benjamin Borgo), engineering (VP Mark Webb), business development (VP Jacob Lesnik), and chief of staff (Stefan Arteaga). The company has expanded its biotech industry partnerships in tandem with its Series A, signaling an intent to broaden its commercial footprint, though no named customer accounts or revenue figures have been disclosed.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy delivery, intracellular drug delivery, nano-needle platform, non-viral gene delivery, cell engineering systems
Industry1 code
PRIMARYHDAHALAO
Sensor Fusion, Interface ICs & Modules (AFE/Readout/Packaging/Calibration)
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Nanotechnology541713
SIC code1 code
  • Laboratory Analytical Instruments3826
Product category
Cell Therapy Delivery Instruments
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biotech Platform/System Sales
TypeOne Time License
Description

Mekonos develops and commercializes its Iris system-on-a-chip platform for drug delivery applications in the biotech industry. The company raised Series A funding in 2021 indicating a pre-commercial or early commercial stage.

matu.co.nz
Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Iris
Description

System-on-a-chip platform for drug delivery to cells using nano-needles.

matu.co.nz
Core offering1 text field

Mekonos develops and commercializes the Iris™ platform, a system-on-a-chip that uses arrays of nano-needles to deliver therapeutic cargo directly into cells with single-cell precision. The platform targets pharmaceutical companies and research institutions working on cell therapies, gene editing, and intracellular drug delivery applications.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Mekonos offers a single unified product called Iris™, a system-on-a-chip platform that enables precision drug delivery to cells through nano-needle technology. The platform is designed for pharmaceutical and biotech applications requiring targeted intracellular delivery.

Product and service1 record
1Iris™ System-on-a-Chip Platform
CategoryCell therapy and gene-editing delivery platform
Description

A proprietary system-on-a-chip platform that uses arrays of nano-needles to deliver therapeutic cargo — including mRNA, CRISPR, proteins, and small molecules — directly into cells with single-cell precision. It is sold to biopharmaceutical companies and research institutions developing cell therapies, gene-editing programs, and intracellular drug-delivery workflows as an alternative to electroporation, viral vectors, and lipid nanoparticles.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Mekonos expanded its partnerships across the biotech industries in 2021 following Series A funding. These partnerships focus on collaboration within the biotech sector for drug delivery applications using the Iris platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

MaxCyte provides electroporation-based cell transfection instruments and processing services used in cell and gene therapy manufacturing. It is the most directly comparable commercial-stage intracellular-delivery platform peer for Mekonos's Iris.

TypeBroad incumbent
Description

Lonza is a global CDMO and tools provider with cell-therapy manufacturing services and process-development platforms. It overlaps with Mekonos in serving pharma and biotech customers building cell-therapy workflows, but at much broader scale.

TypeBroad incumbent
Description

Thermo Fisher supplies a broad portfolio of cell-engineering instruments, reagents, and services through its bioscience and pharma services segments. It is a broad incumbent competing for the same biotech and pharma customers that Mekonos targets.

TypeDirect peer
Description

Miltenyi Biotec provides cell-processing instruments, reagents, and closed-system manufacturing solutions used in cell and gene therapy. It competes with Mekonos in intracellular and cell-engineering workflows for biotech and pharma research.

TypeBroad incumbent
Description

BD's biosciences segment offers cell-sorting, cell-engineering, and discovery instrumentation used by pharma and biotech researchers. It overlaps with Mekonos's customer base and core cell-therapy workflows, but across a much broader product portfolio.

TypeEmerging player
Description

NanoCellect develops microfluidic cell-sorting and analysis platforms for cell engineering. It is an emerging peer in cell-handling instrumentation with comparable biotech/pharma research customers, though focused on sorting rather than delivery.

TypeEmerging player
Description

Celetrix provides electroporation-based transfection instruments for cell and gene therapy research. It is an emerging player competing for the same intracellular-delivery use case as Mekonos's Iris nano-needle platform.

TypeBroad incumbent
Description

Stemcell Technologies supplies cell-isolation, culture, and engineering tools to academic and biotech researchers. It is an adjacent incumbent serving overlapping pharma/biotech research customers with cell-handling products.

9CytoPlex (Curiox Biosystems)
TypeEmerging player
Description

Curiox develops microfluidic and nanofluidic cell-processing platforms used in cell therapy and immunology research. It is an emerging peer in miniaturized cell-handling instrumentation relevant to Mekonos's nano-needle SoC approach.

TypeOthers
Description

Abcam supplies research reagents, antibodies, and cell-engineering tools to pharma and academic researchers. It is an adjacent ecosystem participant whose customers overlap with Mekonos's biotech research buyer base.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mekonos

Cell Therapy Delivery Instrumentsmekonos.com

What Mekonos does

Mekonos is a privately held biotech tools company founded in 2017 and headquartered in Alameda, California (Silicon Valley). It develops and commercializes Iris™, a proprietary system-on-a-chip platform that uses nano-needle technology to deliver payloads directly into cells, targeting pharmaceutical companies and research institutions working on cell therapies, gene therapies, and intracellular drug discovery. The platform is positioned as a more precise and less disruptive alternative to conventional intracellular delivery methods such as viral vectors, electroporation, and lipofection, with applications spanning ex vivo cell engineering and broader biotech research workflows.

The company's core technology centers on a semiconductor chip bearing arrays of nanoscale needles that physically interface with individual cells to deliver cargo, a method-architecture distinct from incumbent approaches. Its revenue model is described as one-time license/system sales of the Iris platform, and its go-to-market is enterprise field sales targeting biotech and pharmaceutical accounts. The company is venture-backed, having raised approximately $31 million cumulatively across seed, early, and Series A rounds between 2017 and 2021, with strategic investors including Novartis and Debiopharm Innovation Fund alongside deep-tech-focused capital such as TDK Ventures.

Mekonos operates with a team of 11–50 employees led by founder and CEO Anil Narasimha, with a leadership bench spanning operations (COO Benjamin Borgo), engineering (VP Mark Webb), business development (VP Jacob Lesnik), and chief of staff (Stefan Arteaga). The company has expanded its biotech industry partnerships in tandem with its Series A, signaling an intent to broaden its commercial footprint, though no named customer accounts or revenue figures have been disclosed.

Mekonos firmographics

Firmographics
Name
Mekonos
Website
https://mekonos.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Mekonos industry classification

Industry
Product category
Cell Therapy Delivery Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Research and Development in Nanotechnology (541713)
SIC
Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHDAHALAO
Sensor Fusion, Interface ICs & Modules (AFE/Readout/Packaging/Calibration)

Keywords

  • Cell therapy delivery
  • Intracellular drug delivery
  • Nano-needle platform
  • Non-viral gene delivery
  • Cell engineering systems

Where Mekonos is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mekonos business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Biotech Platform/System Sales: Mekonos develops and commercializes its Iris system-on-a-chip platform for drug delivery applications in the biotech industry. The company raised Series A funding in 2021 indicating a pre-commercial or early commercial stage.

Go-to-market motion1 record

Mekonos product offering

Product offering

Core offering

Mekonos develops and commercializes the Iris™ platform, a system-on-a-chip that uses arrays of nano-needles to deliver therapeutic cargo directly into cells with single-cell precision. The platform targets pharmaceutical companies and research institutions working on cell therapies, gene editing, and intracellular drug delivery applications.

Product overview

Mekonos offers a single unified product called Iris™, a system-on-a-chip platform that enables precision drug delivery to cells through nano-needle technology. The platform is designed for pharmaceutical and biotech applications requiring targeted intracellular delivery.

Differentiator

Problem solved

Functional benefit

Brands

  • Iris: System-on-a-chip platform for drug delivery to cells using nano-needles.

Products and services

  • Iris™ System-on-a-Chip Platform A proprietary system-on-a-chip platform that uses arrays of nano-needles to deliver therapeutic cargo — including mRNA, CRISPR, proteins, and small molecules — directly into cells with single-cell precision. It is sold to biopharmaceutical companies and research institutions developing cell therapies, gene-editing programs, and intracellular drug-delivery workflows as an alternative to electroporation, viral vectors, and lipid nanoparticles.

Companies that use Mekonos

Customer profile

Segments1 record

Ideal customer profiles2 records

Mekonos technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mekonos partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Biotech Industry PartnerscoreStrategic or Co-development Partner · 1 January 2021Mekonos expanded its partnerships across the biotech industries in 2021 following Series A funding. These partnerships focus on collaboration within the biotech sector for drug delivery applications using the Iris platform.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Mekonos competitors and assessment

Company assessment

Direct peers

  • MaxCyte: MaxCyte provides electroporation-based cell transfection instruments and processing services used in cell and gene therapy manufacturing. It is the most directly comparable commercial-stage intracellular-delivery platform peer for Mekonos's Iris.
  • Miltenyi Biotec: Miltenyi Biotec provides cell-processing instruments, reagents, and closed-system manufacturing solutions used in cell and gene therapy. It competes with Mekonos in intracellular and cell-engineering workflows for biotech and pharma research.

Broad incumbents

  • Lonza: Lonza is a global CDMO and tools provider with cell-therapy manufacturing services and process-development platforms. It overlaps with Mekonos in serving pharma and biotech customers building cell-therapy workflows, but at much broader scale.
  • Thermo Fisher Scientific: Thermo Fisher supplies a broad portfolio of cell-engineering instruments, reagents, and services through its bioscience and pharma services segments. It is a broad incumbent competing for the same biotech and pharma customers that Mekonos targets.
  • Becton, Dickinson and Company (BD): BD's biosciences segment offers cell-sorting, cell-engineering, and discovery instrumentation used by pharma and biotech researchers. It overlaps with Mekonos's customer base and core cell-therapy workflows, but across a much broader product portfolio.
  • Stemcell Technologies: Stemcell Technologies supplies cell-isolation, culture, and engineering tools to academic and biotech researchers. It is an adjacent incumbent serving overlapping pharma/biotech research customers with cell-handling products.

Emerging players

  • NanoCellect Biomedical: NanoCellect develops microfluidic cell-sorting and analysis platforms for cell engineering. It is an emerging peer in cell-handling instrumentation with comparable biotech/pharma research customers, though focused on sorting rather than delivery.
  • Celetrix: Celetrix provides electroporation-based transfection instruments for cell and gene therapy research. It is an emerging player competing for the same intracellular-delivery use case as Mekonos's Iris nano-needle platform.
  • CytoPlex (Curiox Biosystems): Curiox develops microfluidic and nanofluidic cell-processing platforms used in cell therapy and immunology research. It is an emerging peer in miniaturized cell-handling instrumentation relevant to Mekonos's nano-needle SoC approach.

Others

  • abcam: Abcam supplies research reagents, antibodies, and cell-engineering tools to pharma and academic researchers. It is an adjacent ecosystem participant whose customers overlap with Mekonos's biotech research buyer base.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Mekonos social profiles

Digital presence

Mekonos financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mekonos leadership team

Management profile

Number of profiles

Profiles5 records

Mekonos funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mekonos M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mekonos

What does Mekonos do?

Mekonos develops and commercializes the Iris™ platform, a system-on-a-chip that uses arrays of nano-needles to deliver therapeutic cargo directly into cells with single-cell precision. The platform targets pharmaceutical companies and research institutions working on cell therapies, gene editing, and intracellular drug delivery applications.

Is Mekonos a public or private company?

Mekonos is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mekonos founded?

Mekonos was founded in 2017. It employs 1 to 10 people.

Where is Mekonos based?

Mekonos is headquartered in San Francisco, United States, in the North America region.

How does Mekonos make money?

One revenue line is on record: biotech Platform/System Sales.

Who are Mekonos's main competitors?

Direct peers on record are MaxCyte and Miltenyi Biotec. Broad incumbents are Lonza, Thermo Fisher Scientific, Becton, Dickinson and Company (BD) and Stemcell Technologies. Emerging players are NanoCellect Biomedical, Celetrix and CytoPlex (Curiox Biosystems). abcam is listed as an others.

Does Mekonos have an API?

No public API is recorded for Mekonos.

What industry is Mekonos in?

Mekonos's product category is Cell Therapy Delivery Instruments. Its primary akta.pro industry code is HDAHALAO, Sensor Fusion, Interface ICs & Modules (AFE/Readout/Packaging/Calibration). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogMekonos Announces Research Collaboration With bit.bio to Advance Cell EngineeringMekonos announced a research collaboration with bit.bio to test non-viral delivery of bit.bio's opti-ox precision cellular reprogramming technology. The partnership aims to engineer human induced pluripotent stem cells into mature cell types with higher efficiency and control. Initial results are expected mid-year.PR NewswireMekonos to Present at 2023 Cell & Gene Meeting on the MedMekonos announced that CEO Dr. Anil Narasimha will present at the Cell & Gene Meeting on the Med in Barcelona on April 13, 2023. The company's ex vivo nanoneedle-based delivery system enables high-efficiency cargo delivery into any cell type. The conference features over 60 company presentations and 100 panelists.Startupill19 Best San Francisco Semiconductor Startups – Impacting The Electronics IndustryThe article profiles 19 San Francisco-based semiconductor startups, including Tempo Automation, Diamond Foundry, and Mekonos, highlighting their innovative approaches. The companies span areas such as cell therapies, sensors, and FPGA mining, with data sourced from Crunchbase and SemRush.PR NewswireOpentrons' subsidiary Neochromosome and Mekonos announce new partnership to advance cell engineering for personalized medicineMekonos, Inc. has announced a new partnership with Neochromosome, Inc., a wholly-owned subsidiary of Opentrons Labworks, to develop advanced cell and gene therapies for personalized medicine using synthetic biology technologies. The collaboration will leverage Neochromosome's de novo synthesized Big-DNA cargo and Mekonos' proprietary Iris chip-based delivery technology to engineer human induced pluripotent stem cells for treating diseases including diabetes, Parkinson's, and cancer. The research collaboration launches in January 2022 in the San Francisco Bay Area, with initial results expected mid-year.FinSMEsMekonos Raises $25M in Series A FundingMekonos, a San Francisco-based biotech firm, has raised $25 million in Series A funding. The funding round was led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital, among others, to enhance its chip technology platform for targeted gene engineering and expand commercial partnerships. The company aims to accelerate its research and development efforts to improve cell engineering capabilities.PR NewswireTDK Ventures backs MEMS-based genome editing tools company, MekonosTDK Ventures invested in Mekonos, a biotech tools company developing a MEMS-based integrated molecular delivery chip for cell and gene therapies. The chip aims to scale and improve precision in transfection, addressing inefficiencies in current methods. Mekonos raised a $25M Series A round co-led by Reimagined Ventures and Fiscus Financial.PR NewswireBiotech Startup Mekonos raises oversubscribed $25 million round to overcome pharma industry's cell & gene therapy delivery hurdlesMekonos raised $25 million in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital. The funding will accelerate development of its System on a Chip for cell therapy delivery and expand commercial partnerships. The company plans to use the capital to advance its proprietary chip technology and talent acquisition.MatuMekonosMekonos, a biotechnology company based in Silicon Valley, has developed Iris™, a system-on-a-chip platform designed to deliver drug payloads to individual cells with higher efficiency than traditional virus-based methods. The company closed a USD$25 million Series A capital raise in 2021 to expand its technology and intellectual property portfolio. This funding enabled Mekonos to establish several strategic partnerships across the biotech industry.BioSpaceBiotech Startup Mekonos raises oversubscribed $25 million round to overcome pharma industry’s cell & gene therapy delivery hurdlesBiotech startup Mekonos has raised $25 million in an oversubscribed Series A funding round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital. The capital will support the development and commercialization of its novel chip technology platform designed for precise, scalable ex-vivo delivery of cell payloads. This investment follows pilot projects with major pharmaceutical partners demonstrating high viability in CRISPR and other payload deliveries.VC News DailyMekonos Raises $25M Series A RoundMekonos, a San Francisco-based biotech company developing cell therapies on a chip, has raised $25 million in an oversubscribed Series A round co-led by Reimagined Ventures, Fiscus Ventures, and PEAK6 Strategic Capital. The funding round also included participation from Section 32, Sands Capital, TDK Ventures, Debiopharm's venture arm, Novartis Pharma AG, and Elementum Ventures, and will support the company's product development and commercialization efforts. The company's System-on-Chip technology integrates MEMS, microfluidics, and chemistry for controlled molecular delivery in cells at scale.